GEN1286 for Advanced Solid Tumors

This clinical trial is designed to study a new medication called GEN1286 for people with advanced solid tumors. Solid tumors are abnormal masses of tissue that usually don't contain cysts or liquid areas, and they can occur in various parts of the body, like the breast, lung, or liver. The study aims to determine if GEN1286 is safe and tolerable for patients, how the body processes the drug, and its potential to fight tumors. Additionally, researchers will observe if the drug causes any immune response. This study is important because finding effective treatments for advanced tumors can improve outcomes and provide new options for patients. Participants in the study will receive GEN1286 in two main phases. In the first part, the dose of GEN1286 will be gradually increased to identify the safest and most effective amount. Once an optimal dose is found, the second part will focus on specific types of tumors to further explore the drug's effects. Participants will be closely monitored to see how their bodies react to the treatment, and any changes in their tumors will be documented. The study seeks to understand the drug's properties thoroughly, including any potential risks or unexpected reactions.